Daniel Lovell, MD, MPH
Cincinnati Children's Hospital Medical Center
Cincinnati, OH, United States
Disclosure(s): Bristol-Myers Squibb(BMS): Consultant (Ongoing); Janssen: Consultant (Ongoing); Pfizer: Consultant (Ongoing)
Richard Vehe, MD
University of Minnesota
Roseville, MN, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
This session will introduce draft updates to the ACR guidelines for Juvenile Idiopathic Arthritis (JIA), building upon the 2019 and 2021 guidelines. We will incorporate the latest evidence and expert consensus to refine recommendations across systemic JIA, non-systemic JIA, and JIA-associated uveitis. Attendees will gain insights into the rationale behind these updates and their implications for clinical practice.
Speaker: Karen Onel, MD – HSS
Speaker: Daniel Horton, MD, MS – Rutgers Robert Wood Johnson Medical School
Speaker: Sheila Angeles-Han, MD, MSc – Cincinnati Children's Hospital